Clinical Trial Update: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BKM120 as monotherapy in metastatic head and neck cancer with recurrent or progressive disease; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Head and Neck Neoplasms, Neoplasm Metastasis | Phase 2 | Status: COMPLETED